secwatch.observer — SEC 8-K summary
======================================

Issuer:     Wave Life Sciences Ltd. (WVE)
CIK:        0001631574
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001193125-25-194511
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Wave Life Sciences reports positive WVE-006 data in alpha-1 antitrypsin deficiency study
--------------------------------------------------------------------------------

- 200 mg repeat doses achieved 11.9 µM total AAT and 7.2 µM M-AAT, meeting therapeutic levels
- Individual during acute phase response showed 20.6 µM total AAT and 10.3 µM M-AAT, first demonstration of restored physiological production
- Single 400 mg dose achieved 12.8 µM total AAT and 5.3 µM M-AAT; monthly dosing supported
- GSK holds exclusive global license for WVE-006; Wave eligible for up to $525M milestones plus royalties
- Data support monthly or less frequent subcutaneous dosing; 400 mg multidose cohort data expected Q1 2026

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/0001193125-25-194511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1631574/000119312525194511/d67509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-194511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer